Parhelia Biosciences, an Austin, TX-based company which specializes in sample preparation for tissue staining and spatial analysis, raised an undisclosed amount in Series A funding.
The round saw participation from Rabbit Run Partners, Thielsen Capital, and industry angels.
The company intends to use the funds to accelerate its growth, scale its support, commercial efforts, and pursue strategic collaborations.
Led by CEO Dr. Nikolay Samuisk, Parhelia Biosciences is dedicated to providing auto-staining devices that are compact, affordable, flexible, and easy to use for staining automation. The company’s devices have the potential to transform and expand sample preparation for a wide menu of spatial protocols including those already supported – Phenocycler (formerly CODEX) and Phenoptics (formerly Opal), immunohistochemistry (IHC), hematoxylin and eosin (H&E) staining, RNAScope, immunofluorescence (including CYCIF), and imaging mass cytometry (IMC).
Parhelia Biosciences has placements across leading academic institutions and biopharma.
